Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development
AlphaVax Inc
Helocyte Biosciences Inc
Hookipa Pharma Inc
Immunomic Therapeutics Inc
Moder Inc
VBI Vaccines Inc
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles
AVX-601 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
Product Description
Mechanism Of Action
History of Events
cytomegalovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
cytomegalovirus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HB-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ITI-1000 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ITI-1001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
mR-1443 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Triplex - Drug Profile
Product Description
Mechanism Of Action
History of Events
Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine - Drug Profile
Product Description
Mechanism Of Action
VBI-1901 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Products
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones
Featured News & Press Releases
Jun 22, 2022: VBI vaccines receives U.S. FDA Orphan Drug Desigtion for VBI-1901 for the treatment of glioblastoma
Jun 06, 2022: VBI Vaccines presents updated phase 2a tumor response and overall survival data for VBI-1901 in recurrent GBM at the 2022 ASCO Annual Meeting
Apr 28, 2022: VBI Vaccines announces data from VBI-1901 in recurrent glioblastoma patients selected for poster discussion at the 2022 ASCO Annual Meeting
Apr 14, 2022: Immunomic Therapeutics to participate at World Vaccine Congress Washington 2022
Jan 26, 2022: VBI Vaccines to participate in the B. Riley Securities 2022 Oncology Investor Conference
Jan 06, 2022: Immunomic Therapeutics CBO to present at the 14th Annual Biotech Showcase Event
Dec 17, 2021: Fortress and Helocyte begin Phase II trial of cytomegalovirus vaccine
Dec 01, 2021: VBI Vaccines to present new overall survival data from phase 2a study in recurrent GBM at the World Vaccine & Immunotherapy Congress 2021
Nov 30, 2021: Immunomic Therapeutics announces open enrollment for RENEW clinical study of CMV R-pulsed dendritic cell vaccine for the treatment of newly-diagnosed glioblastoma patients
Nov 18, 2021: Immunomic Therapeutics presents clinical data from ATTAC studies in GBM at the 2021 Society for Neurology (SNO) Annual Meeting
Nov 09, 2021: HOOKIPA announced Phase 2 data on HB-101
Jun 08, 2021: VBI Vaccines granted FDA fast track desigtion for VBI-1901 for the treatment of recurrent GBM
May 20, 2021: VBI Vaccines to present updated phase 2a tumor response and overall survival data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
Feb 02, 2021: Immunomic Therapeutics’ CEO to present at the BIO CEO & Investor Digital Conference
Jan 05, 2021: Immunomic Therapeutics’ CEO to present at the 13th Annual Biotech Showcase Digital Event
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AlphaVax Inc, 2022
Pipeline by Helocyte Biosciences Inc, 2022
Pipeline by Hookipa Pharma Inc, 2022
Pipeline by Immunomic Therapeutics Inc, 2022
Pipeline by Moderna Inc, 2022
Pipeline by VBI Vaccines Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022